Serum Institute and Gates MRI Partner to Accelerate Global Tuberculosis Vaccine Production

DNI SUMMARY — KEY POINTS

• The Gates Medical Research Institute and the Serum Institute of India have formed a strategic partnership to manufacture the novel M72/AS01E tuberculosis vaccine candidate.
• This collaboration aims to prepare for large-scale production of the potential vaccine to ensure rapid access for high-burden countries immediately upon regulatory approval.
• Serum Institute of India has committed an investment exceeding 100 million dollars to enhance its manufacturing infrastructure and overall capacity for this critical public health project.
• The vaccine candidate is currently undergoing a massive Phase 3 clinical trial involving 20,000 participants across several countries including South Africa, Kenya, Malawi, Zambia, and Indonesia.
• GlaxoSmithKline will continue its involvement by supplying the necessary AS01E adjuvant, building upon its decades of research and development for the TB vaccine candidate.

The Gates Medical Research Institute and the Serum Institute of India have officially signed an agreement to manufacture the novel tuberculosis vaccine candidate known as M72/AS01E. This partnership represents a significant milestone in the global effort to combat tuberculosis, a disease that continues to be the leading infectious cause of death worldwide. By combining the research expertise of the institute with the massive, proven production capabilities of the Indian manufacturer, the collaboration seeks to eliminate the typical delays associated with vaccine scaling once regulatory approval is finally granted.

Scaling Up Global Vaccine Production

The manufacturing arrangement focuses on the potential delivery of the first new tuberculosis vaccine in over a century. If successful, this intervention could fundamentally change the landscape of infectious disease control in low- and middle-income countries where the burden of the illness is disproportionately high. The Serum Institute was chosen specifically for its long-standing record of producing WHO-prequalified vaccines at scale and its adherence to stringent international regulatory standards that ensure both safety and consistency in global health supplies.

Financial commitments underscore the seriousness of this initiative, with the Pune-based manufacturer pledging to invest more than 100 million dollars of its own capital. These funds are designated to strengthen manufacturing readiness and expand facility capacity to ensure the supply chain is robust enough to meet future global demand. GlaxoSmithKline will also play a vital role in this endeavor as the original developer, tasked with supplying the crucial AS01E adjuvant required for the vaccine's efficacy and proper function during administration.

Proactive Strategy During Clinical Trials

Strategic planning for technology transfer is already underway, occurring well ahead of the final results from the ongoing Phase 3 trials. By initiating this complex technical handover now, the partners are adopting a deliberate strategy to shave months or even years off the timeline for mass distribution. This proactive approach ensures that the logistical pathways for manufacturing the antigen and managing the adjuvant supply are fully operational, allowing for immediate production cycles should the vaccine demonstrate the necessary safety and clinical success.

The Phase 3 clinical trial currently underway is a massive, double-blind, randomized study that reached full enrollment in April 2025. With 20,000 participants spread across 54 distinct sites in Africa and Indonesia, the trial represents one of the largest efforts ever undertaken to test a tuberculosis vaccine candidate in adults and adolescents. Funding for this extensive operation is provided primarily by the Gates Foundation and Wellcome, reflecting a deep-seated commitment to addressing the urgent health crisis posed by this ancient, yet still lethal, bacterial infection.

Investing In Human Health Impact

Health experts suggest that the successful implementation of this vaccine could have a profound economic and humanitarian impact on the most affected communities. Data from previous trials indicates that a vaccine with approximately 50 percent efficacy could prevent tens of millions of new cases and save millions of lives over the next few decades. Beyond the human toll, the reduction in disease burden is projected to save billions of dollars in health expenses for affected households, offering a path to better fiscal and social stability.

Public health initiatives in the past have frequently struggled with the gap between scientific breakthrough and equitable distribution, particularly in regions with limited resources. This new agreement aims to bridge that divide by involving local manufacturers in countries such as South Africa and Indonesia to support the supply chain. This decentralized strategy is designed to ensure that when the vaccine is approved, the rollout is not confined to wealthy nations but reaches those individuals at highest risk in the most vulnerable populations.

Redefining Vaccine Distribution Partnerships

The broader implications of this agreement extend to how global health organizations approach the production of vaccines for neglected diseases. By aligning a major research institute with a high-capacity manufacturing partner, the project serves as a model for future collaborations involving complex biological products. As the trial progresses toward its conclusion, the spotlight will remain on the M72/AS01E candidate and its potential to finally provide a reliable, scalable defense against a pathogen that has claimed countless lives for generations without a modern, effective vaccine solution.